KemPharm, Inc. (KMPH) Scheduled to Post Earnings on Tuesday
KemPharm, Inc. (NASDAQ:KMPH) will release its earnings data after the market closes on Tuesday, November 7th. Analysts expect KemPharm to post earnings of ($0.67) per share for the quarter.
KemPharm (NASDAQ:KMPH) last posted its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.19. On average, analysts expect KemPharm to post $-2.7 EPS for the current fiscal year and $-2.61 EPS for the next fiscal year.
KemPharm, Inc. (NASDAQ KMPH) opened at 3.75 on Tuesday. The company’s market cap is $54.96 million. KemPharm, Inc. has a 52-week low of $2.45 and a 52-week high of $5.40. The firm’s 50 day moving average is $3.72 and its 200 day moving average is $3.67.
In related news, major shareholder Delaware Street Capital Master acquired 325,888 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were bought at an average price of $3.27 per share, for a total transaction of $1,065,653.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have purchased 335,188 shares of company stock worth $1,090,088. 22.80% of the stock is owned by insiders.
KMPH has been the topic of a number of recent analyst reports. ValuEngine cut shares of KemPharm from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Zacks Investment Research upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Canaccord Genuity set a $7.00 price target on shares of KemPharm and gave the company a “buy” rating in a report on Thursday, August 10th. Finally, Oppenheimer Holdings, Inc. set a $13.00 price target on shares of KemPharm and gave the company a “buy” rating in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $9.00.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.